Patents Assigned to Zentaris AG
-
Patent number: 7378522Abstract: The invention relates to new quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone.Type: GrantFiled: July 23, 2004Date of Patent: May 27, 2008Assignee: Zentaris AGInventors: Peter Strehlke, Peter Droescher, Ulrich Buehmann, Norbert Schmees, Peter Muhn, Holger Hess-Stumpp, Roland Kühne, Eckhard Guenther, Emmanuel Polymeropoulos, Antonius M. Ter Laak
-
Patent number: 7122570Abstract: This invention provides new tetrahydrocarbazole derivatives that act as ligands for G-protein-coupled receptors (GPCR), especially as antagonists of the gonadotropin-releasing hormone (GnRH). A pharmaceutical composition that contains these new tetrahydrocarbazole derivatives as well as a process for the production of the new tetrahydrocarbazole derivatives are also provided. Moreover, this invention relates to the administration of tetrahydrocarbazole derivatives for treating pathologic conditions that are mediated by GPCR, especially for inhibiting GnRH, in mammals, especially humans, who require such an administration, as well as the use of tetrahydrocarbazole derivatives for the production of a pharmaceutical agent for treating GPCR-mediated pathologic conditions, especially for inhibiting GnRH.Type: GrantFiled: December 16, 2002Date of Patent: October 17, 2006Assignee: Zentaris AGInventors: Marcus Karl Koppitz, Hans Peter Muhn, Kenneth Jay Shaw, Holger Hess-Stump, Klaus Paulini
-
Patent number: 6890926Abstract: The invention relates to novel quinoline derivatives of the formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.Type: GrantFiled: July 20, 2001Date of Patent: May 10, 2005Assignee: Zentaris AGInventors: Peter Emig, Eckhard Günther, Jürgen Schmidt, Bernd Nickel, Bernhard Kutscher
-
Patent number: 6863891Abstract: A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.Type: GrantFiled: January 9, 2002Date of Patent: March 8, 2005Assignee: Zentaris AGInventors: Jürgen Engel, Burkhard Wichert, Dieter Sauerbier, Thomas Reissmann
-
Patent number: 6861409Abstract: The invention relates to compounds of formula I which are useful for elevating the plasma level of growth hormone in a mammal as well for the treatment of growth hormone secretion deficiency, growth retardation in child and metabolic disorders associated with growth hormone secretion deficiency.Type: GrantFiled: June 13, 2001Date of Patent: March 1, 2005Assignee: Zentaris AGInventors: Jean Martinez, Jean-Alain Fehrentz, Vincent Guerlavais
-
Patent number: 6849715Abstract: A method of treating a disorder characterized by an activating mutation in a Ras proto-oncogene, comprising contacting cells of a patient suffering from the disorder with a protein having the toxic activity of Clostridium sordellii toxin LT under conditions favoring inactivation of Ras by glucosylation of Ras' threonine 35 in said cell. The protein preferably is an immunotoxin that contains as a toxic domain the catalytic domain of toxin LT.Type: GrantFiled: July 31, 1998Date of Patent: February 1, 2005Assignee: Zentaris AGInventors: Christoph Von Eichel-Streiber, Patrice Boquet, Monica Thelestam
-
Publication number: 20040229823Abstract: The invention relates to compounds of formula I 1Type: ApplicationFiled: May 4, 2004Publication date: November 18, 2004Applicant: Zentaris AGInventors: Jean Martinez, Jean-Alain Fehrentz, Vincent Guerlavais
-
Patent number: 6812243Abstract: The invention relates to tyrosine kinase inhibitors of the bis-indolyl compound type of the general formula I: pharmaceuticals containing them and their use for the treatment of malignant and other diseases based on pathological cell proliferation.Type: GrantFiled: May 3, 2002Date of Patent: November 2, 2004Assignee: Zentaris AGInventors: Siavosh Mahboobi, Sabine Kuhr, Herwig Pongratz, Alfred Popp, Harald Hufsky, Frank-D Bohmer, Steffen Teller, Andrea Uecker, Thomas Beckers
-
Patent number: 6790858Abstract: The present invention relates to a compound of formula (I): where R1-R6, W, X, and Y are defined herein, a composition includung the compound of formula (I), and a method for, e.g., male birth control, including administering an effective amount of a compound of formula (I) to a patient in need thereof.Type: GrantFiled: February 21, 2002Date of Patent: September 14, 2004Assignee: Zentaris AGInventors: Peter Strehlke, Peter Droescher, Ulrich Buehmann, Norbert Schmees, Peter Muhn, Holger Hess-Stumpp, Roland Kühne, Eckhard Guenther, Emmanuel Polymeropoulos, Antonius M. Ter Laak
-
Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds
Patent number: 6727252Abstract: The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with 5-azaquinoxaline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to 5-azaquinoxaline compounds and pharmaceutical compositions comprising these compounds.Type: GrantFiled: October 16, 2000Date of Patent: April 27, 2004Assignee: Zentaris AGInventors: Gerald McMahon, Heinz Weinberger, Bernhard Kutscher, Harald App -
Patent number: 6716817Abstract: A method of treating female infertility using a novel cetrorelix acetate lyophilizate is disclosed.Type: GrantFiled: January 20, 1999Date of Patent: April 6, 2004Assignee: Zentaris AGInventors: Jürgen Engel, Burkhard Wichert, Dieter Eauerbiar, Thomas Reissman
-
Patent number: 6706722Abstract: The invention relates to novel acridine derivatives of formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.Type: GrantFiled: July 20, 2001Date of Patent: March 16, 2004Assignee: Zentaris AGInventors: Peter Emig, Eckhard Günther, Bernd Nickel, Gerhard Bacher, Silke Baasner, Thomas Beckers, Beate Aue
-
Patent number: 6696428Abstract: The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.Type: GrantFiled: August 2, 2002Date of Patent: February 24, 2004Assignee: Zentaris AGInventors: Bernd Nickel, Peter Hilgard, Thomas Klenner, Jürgen Engel
-
Patent number: 6638935Abstract: The invention relates to novel pyridine derivatives of formula 1, to their preparation and to their use as medicaments, in particular for treating tumorsType: GrantFiled: July 20, 2001Date of Patent: October 28, 2003Assignee: Zentaris AGInventors: Peter Emig, Eckhard Günther, Bernhard Kutscher, Bernd Nickel, Jürgen Schmidt, Anita Storch
-
Patent number: 6627609Abstract: The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. Medicaments in which the peptides according to the invention are contained can be used for the treatment of hormone-dependent tumours and hormone-influenced non-malignant disorders.Type: GrantFiled: March 14, 2000Date of Patent: September 30, 2003Assignee: Zentaris AGInventors: Michael Bernd, Bernhard Kutscher, Eckhard Günther, Peter Romeis, Thomas Reissmann, Thomas Beckers
-
Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds
Publication number: 20030181480Abstract: The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with azabenzimidazole-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to azabenzimidazole compounds and pharmaceutical compositions comprising these compounds.Type: ApplicationFiled: November 15, 2002Publication date: September 25, 2003Applicant: Zentaris AGInventors: Gerald McMahon, Heinz Weinberger, Bernhard Kutscher, Harald App -
Publication number: 20030153533Abstract: Novel phospholipid derivatives of the General Formula I: 1Type: ApplicationFiled: November 8, 2002Publication date: August 14, 2003Applicant: Zentaris AGInventors: Gerhard Nossner, Bernhard Kutscher, Jurgen Engel, Wolfgang Schumacher, Jurij Stekar, Peter Hilgard
-
Patent number: 6576624Abstract: The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.Type: GrantFiled: June 23, 2000Date of Patent: June 10, 2003Assignee: Zentaris AGInventors: Bernd Nickel, Peter Hilgard, Thomas Klenner, Jürgen Engel
-
Patent number: 6544551Abstract: The present invention relates to new solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, a process for the manufacture of said pharmaceutical composition, a dosage scheme for oral administration of said pharmaceutical composition in the treatment of leishmaniasis, and finally a combination comprising said solid pharmaceutical composition, antiemeticum, and/or an antidiarrhoeal.Type: GrantFiled: July 24, 2000Date of Patent: April 8, 2003Assignee: Zentaris AGInventors: Juergen Engel, Werner Sarlikiotis, Thomas Klenner, Peter Hilgard, Dieter Sauerbier, Eckhard Milsmann
-
Patent number: 6506393Abstract: The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I in which R1 is a saturated or monounsaturated or polyunsaturated hydrocarbon residue with 12 to 20 C atoms and R2, R3 and R4 denote independently of one another hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group whereby two of the residues R2, R3 and R4 can together form a C2-C5 alkylene group which, if desired, can be substituted with an —O—, —S— or NR5 group, in which R5 is hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group as well as, if desired the usual pharmaceutical auxiliary, diluting, carrier or/and filling substances.Type: GrantFiled: March 7, 2001Date of Patent: January 14, 2003Assignees: Zentaris AG, Max-Planck Gesellschaft zur Forderung der Wissenchaften e.V.Inventors: Hansjörg Eibl, Clemens Unger, Jürgen Engel